Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Regulation FD Disclosure
Item 7.01.Regulation FD Disclosure.
On January 5, 2017, Rennova Health, Inc. (the Company) issued a
press release to provide an outlook for 2017 and, as previously
announced, that it will hold a conference call and provide a
business update on January 5, 2017 to discuss the Company’s
business strategy as well as its milestones and expectations for
2017. The conference call is scheduled to begin at 4:30 p.m. ET.
A copy of the press release is attached as Exhibit 99.1 to this
report.
The information furnished to this Item 7.01, including Exhibit
99.1, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities under that Section and shall not be
deemed to be incorporated by reference into any filing of the
Company under the Securities Act of 1933 or the Exchange Act,
except as shall be expressly set forth by specific reference in
such filing.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Exhibit Description |
|
| 99.1 | Press release dated January 5, 2017 | |
About Rennova Health, Inc. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc. Rennova Health, Inc. (NASDAQ:RNVA) Recent Trading Information
Rennova Health, Inc. (NASDAQ:RNVA) closed its last trading session up +0.0027 at 0.0885 with 17,307,013 shares trading hands.